We demonstrated here that pharmacological blockade of IL-1 signaling by IL-1Ra administration is sufficient to improve hepatic steatosis and the metabolic profile in DIO mice (Figs. 7–8). The gene discussed is IL1A; the disease is fatty liver disease.